Droxicam

Drug Profile

Droxicam

Alternative Names: Dobenam; Droflex; Drogelon; Droxar; E 3128; Ferpan; Precam

Latest Information Update: 29 Apr 2003

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Esteve
  • Developer Almirall-Prodesfarma; Angelini Group; Esteve; Johnson & Johnson
  • Class Antirheumatics; Nonsteroidal anti-inflammatories; Pyridines; Small molecules
  • Mechanism of Action Prostaglandin synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Market Withdrawal Rheumatic disorders

Most Recent Events

  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
  • 01 Sep 1995 Launched for Rheumatic disorders in Pakistan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top